Annals of Oncology 13:910-918, 2002
© 2002 European Society for Medical Oncology
Original Paper |
EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx®, Doxil®) at a 6-week interval in patients with metastatic breast cancer
1IDBBC, Brussels, Belgium; 2Weston Park Hospital, Sheffield, UK; 3Fondation Bergonié, Bordeaux, France; 4Institut Jules Bordet, Brussels, Belgium; 5Academisch Ziekenhuis Leiden, Leiden, The Netherlands; 6Universiteit Ziekenhuis Nijmegen, Nijmegen, The Netherlands; 7Antoni van Leeuwenhoekhuis, Amsterdam, The Netherlands
Received 26 November 2001; accepted 19 December 2001.
Background
We performed a phase I study of polyethylene glycol (pegylated, Stealth®) liposomal doxorubicin (Caelyx®, Doxil®) using a prolonged (6-week) dose interval to reduce the incidence of skin toxicity that was dose-limiting at more conventional dose intervals, and which appeared to be schedule dependent.
Patients and methods
Eligible for the study were metastatic breast cancer patients who had received a maximum of one prior therapy for metastatic disease. The defined dose levels were 60, 70, 80 and 90 mg/m2.
Results
Twenty patients were assessed at starting doses of 60 mg/m2 (n = 9) or 70 mg/m2 (n = 11). The dose-limiting toxicity was mucositis. Severe skin toxicity was not observed at the 60 mg/m2 dose level, and occurred in only one patient treated at 70 mg/m2. Significant neutropenia, alopecia, and nausea and vomiting were rare events. No clinical cardiac events occurred, despite a median cumulative doxorubicin dose of 323 mg/m2 (range 5–630 mg/m2). Partial responses were documented in five patients. Pharmacokinetics were assessed in 15 patients, and confirmed the long terminal half-life of the agent (median 77 h) demonstrated in earlier studies.
Conclusions
The recommended dose of Caelyx®/Doxil® using this schedule is 60 mg/m2 every 6 weeks. This is a safe and effective regimen that permits prolonged administration of anthracycline to patients with metastatic breast cancer.
Key words: breast cancer, liposomal doxorubicin, schedule
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. Sonoke, T. Ueda, K. Fujiwara, Y. Sato, K. Takagaki, K. Hirabayashi, T. Ohgi, and J. Yano Tumor Regression in Mice by Delivery of Bcl-2 Small Interfering RNA with Pegylated Cationic Liposomes Cancer Res., November 1, 2008; 68(21): 8843 - 8851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. von Mehren, R. J. Schilder, J. D. Cheng, E. Temmer, T. M. Cardoso, F. G. Renshaw, E. Bayever, P. Zannikos, Z. Yuan, and R. B. Cohen A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies Ann. Onc., October 1, 2008; 19(10): 1802 - 1809. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Fujisaka, A. Horiike, T. Shimizu, N. Yamamoto, Y. Yamada, and T. Tamura Phase 1 Clinical Study of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Solid Tumors Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 768 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Kleiter, D. Yu, L. A. Mohammadian, N. Niehaus, I. Spasojevic, L. Sanders, B. L. Viglianti, P. S. Yarmolenko, M. Hauck, N. A. Petry, et al. A Tracer Dose of Technetium-99m-Labeled Liposomes Can Estimate the Effect of Hyperthermia on Intratumoral Doxil Extravasation. Clin. Cancer Res., November 15, 2006; 12(22): 6800 - 6807. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]
|
|
|
|
|
|
E. Briasoulis, G. Pentheroudakis, V. Karavasilis, E. Tzamakou, D. Rammou, and N. Pavlidis Weekly paclitaxel combined with pegylated liposomal doxorubicin (CaelyxTM) given every 4 weeks: dose-finding and pharmacokinetic study in patients with advanced solid tumors Ann. Onc., October 1, 2004; 15(10): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Alexopoulos, M. V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta, and G. Rigatos Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer Ann. Onc., June 1, 2004; 15(6): 891 - 895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. R. Charrois and T. M. Allen Multiple Injections of Pegylated Liposomal Doxorubicin: Pharmacokinetics and Therapeutic Activity J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1058 - 1067. [Abstract] [Full Text] [PDF]
|
|